Literature DB >> 21690484

Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome.

Qi Fu1, Tiffany B Vangundy, Shigeki Shibata, Richard J Auchus, Gordon H Williams, Benjamin D Levine.   

Abstract

We have found recently that exercise training is effective in the treatment of the postural orthostatic tachycardia syndrome (POTS). Whether this nondrug treatment is superior to "standard" drug therapies, such as β-blockade, is unknown. We tested the hypothesis that exercise training but not β-blockade treatment improves symptoms, hemodynamics, and renal-adrenal responses in POTS patients. Nineteen patients (18 women and 1 man) completed a double-blind drug trial (propranolol or placebo) for 4 weeks, followed by 3 months of exercise training. Fifteen age-matched healthy individuals (14 women and 1 man) served as controls. A 2-hour standing test was performed before and after drug treatment and training. Hemodynamics, catecholamines, plasma renin activity, and aldosterone were measured supine and during 2-hour standing. We found that both propranolol and training significantly lowered standing heart rate. Standing cardiac output was lowered after propranolol treatment (P=0.01) but was minimally changed after training. The aldosterone:renin ratio during 2-hour standing remained unchanged after propranolol treatment (4.1±1.7 [SD] before versus 3.9±2.0 after; P=0.46) but modestly increased after training (5.2±2.9 versus 6.5±3.0; P=0.05). Plasma catecholamines were not affected by propranolol or training. Patient quality of life, assessed using the 36-item Short-Form Health Survey, was improved after training (physical functioning score 33±10 before versus 50±9 after; social functioning score 37±9 versus 48±6; both P<0.01) but not after propranolol treatment (34±10 versus 36±11, P=0.63; 39±7 versus 39±5, P=0.73). These results suggest that, for patients with POTS, exercise training is superior to propranolol at restoring upright hemodynamics, normalizing renal-adrenal responsiveness, and improving quality of life.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21690484      PMCID: PMC3142863          DOI: 10.1161/HYPERTENSIONAHA.111.172262

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  40 in total

1.  Determination of catecholamines in human plasma by high-performance liquid chromatography: comparison between a new method with fluorescence detection and an established method with electrochemical detection.

Authors:  F A van der Hoorn; F Boomsma; A J Man in 't Veld; M A Schalekamp
Journal:  J Chromatogr       Date:  1989-01-27

2.  Aldosterone biosynthesis. Interrelationship of regulatory factors.

Authors:  G H Williams; R G Dluhy
Journal:  Am J Med       Date:  1972-11       Impact factor: 4.965

3.  Site of stimulation of aldosterone biosynthesis by angiotensin and potassium.

Authors:  R D Brown; C A Strott; G W Liddle
Journal:  J Clin Invest       Date:  1972-06       Impact factor: 14.808

4.  Noninvasive determination of cardiac output by a modified acetylene rebreathing procedure utilizing mass spectrometer measurements.

Authors:  J H Triebwasser; R L Johnson; R P Burpo; J C Campbell; W C Reardon; C G Blomqvist
Journal:  Aviat Space Environ Med       Date:  1977-03

5.  Confirmation of the optimal pH for measuring renin activity in plasma.

Authors:  P Boer; J H Sleumer; M Spriensma
Journal:  Clin Chem       Date:  1985-01       Impact factor: 8.327

6.  Plasma volume, renin, and vasopressin responses to graded exercise after training.

Authors:  V A Convertino; L C Keil; J E Greenleaf
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1983-02

Review 7.  The pharmacologic alteration of renin release.

Authors:  T K Keeton; W B Campbell
Journal:  Pharmacol Rev       Date:  1980-06       Impact factor: 25.468

8.  Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine.

Authors:  R M Carey; M O Thorner; E M Ortt
Journal:  J Clin Invest       Date:  1980-07       Impact factor: 14.808

9.  Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man. Dopaminergic control of aldosterone.

Authors:  R M Carey; M O Thorner; E M Ortt
Journal:  J Clin Invest       Date:  1979-04       Impact factor: 14.808

10.  Plasma renin and "prorenin" in essential hypertension during sodium depletion, beta-blockade, and reduced arterial pressure.

Authors:  S A Atlas; J E Sealey; J H Laragh; C Moon
Journal:  Lancet       Date:  1977-10-15       Impact factor: 79.321

View more
  43 in total

Review 1.  Postural tachycardia syndrome--current experience and concepts.

Authors:  Christopher J Mathias; David A Low; Valeria Iodice; Andrew P Owens; Mojca Kirbis; Rodney Grahame
Journal:  Nat Rev Neurol       Date:  2011-12-06       Impact factor: 42.937

2.  Gynecologic disorders and menstrual cycle lightheadedness in postural tachycardia syndrome.

Authors:  Kiffany J Peggs; Hovan Nguyen; Diba Enayat; Nancy R Keller; Ayman Al-Hendy; Satish R Raj
Journal:  Int J Gynaecol Obstet       Date:  2012-06-20       Impact factor: 3.561

3.  Short-term exercise training improves the cardiovascular response to exercise in the postural orthostatic tachycardia syndrome.

Authors:  Shigeki Shibata; Qi Fu; Tiffany B Bivens; Jeffrey L Hastings; Wade Wang; Benjamin D Levine
Journal:  J Physiol       Date:  2012-05-28       Impact factor: 5.182

4.  What is brain fog? An evaluation of the symptom in postural tachycardia syndrome.

Authors:  Amanda J Ross; Marvin S Medow; Peter C Rowe; Julian M Stewart
Journal:  Clin Auton Res       Date:  2013-09-03       Impact factor: 4.435

Review 5.  Cognitive and psychological issues in postural tachycardia syndrome.

Authors:  Vidya Raj; Morwenna Opie; Amy C Arnold
Journal:  Auton Neurosci       Date:  2018-03-27       Impact factor: 3.145

6.  2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope.

Authors:  Robert S Sheldon; Blair P Grubb; Brian Olshansky; Win-Kuang Shen; Hugh Calkins; Michele Brignole; Satish R Raj; Andrew D Krahn; Carlos A Morillo; Julian M Stewart; Richard Sutton; Paola Sandroni; Karen J Friday; Denise Tessariol Hachul; Mitchell I Cohen; Dennis H Lau; Kenneth A Mayuga; Jeffrey P Moak; Roopinder K Sandhu; Khalil Kanjwal
Journal:  Heart Rhythm       Date:  2015-05-14       Impact factor: 6.343

Review 7.  Confounders of vasovagal syncope: postural tachycardia syndrome.

Authors:  Victor C Nwazue; Satish R Raj
Journal:  Cardiol Clin       Date:  2013-02       Impact factor: 2.213

8.  Low-dose propranolol and exercise capacity in postural tachycardia syndrome: a randomized study.

Authors:  Amy C Arnold; Luis E Okamoto; André Diedrich; Sachin Y Paranjape; Satish R Raj; Italo Biaggioni; Alfredo Gamboa
Journal:  Neurology       Date:  2013-04-24       Impact factor: 9.910

Review 9.  Exercise in the postural orthostatic tachycardia syndrome.

Authors:  Qi Fu; Benjamin D Levine
Journal:  Auton Neurosci       Date:  2014-11-21       Impact factor: 3.145

Review 10.  Update on the theory and management of orthostatic intolerance and related syndromes in adolescents and children.

Authors:  Julian M Stewart
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.